Skip to main content

emergent-profectus-logo

Maryland biotechnology firms Profectus BioSciences Inc. and Emergent BioSolutions Inc. will receive up to $36 million to develop and manufacture a new vaccine against a type of virus that causes hemorrhagic fever.

{iframe}https://www.bizjournals.com/baltimore/news/2018/08/16/two-marylandbiotechs-get-36-million-to-aid-in-new.html?ana=e_ae_set2&s=article_du&ed=2018-08-16&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1534768436&j=83313021{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.